Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Reading LevelReading Level
-
Content TypeContent Type
-
YearFrom:-To:
-
More FiltersMore FiltersItem TypeIs Full-Text AvailableSubjectPublisherSourceDonorLanguagePlace of PublicationContributorsLocation
Done
Filters
Reset
429
result(s) for
"Jonsson, Michael"
Sort by:
Conflict, Crime, and the State in Postcommunist Eurasia
by
Cornell, Svante E.
,
Jonsson, Michael
in
Afghanistan
,
Bosnia and Herzegovina
,
Bosnia-Hercegovina
2014
In the years after the collapse of the Soviet Union and its zone of influence, few insurgent groups had the resources necessary to confront regular armies. At the same time, state-sponsored financial support for insurgencies dramatically decreased. The pressing need to raise funds for war and the weakness of law enforcement in conflict zones create fertile conditions for organized crime; indeed, there is a mounting body of evidence correlating armed conflict and illicit economy, though the nature of this link and its impact on regional politics has not been well understood.Conflict, Crime, and the State in Postcommunist Eurasiaexplores the relationship between ideologically motivated insurgents, profit-motivated crime, and state institutions in eight conflict zones. Through detailed case studies, the contributors demonstrate how the operations and incentives of insurgents may emerge and shift over time: for some armed groups, crime can become an end in itself beyond a financial means, but not all armed groups equally adapt to illicit commerce. They also show how the criminalization of state institutions is a lingering concerns even after armed conflicts end.Conflict, Crime, and the State in Postcommunist Eurasiaplaces the case studies along a continuum of political and criminal behavior, examining the factors that motivate insurgents to seek out criminal alliance, how this connection affects the dynamics of conflict, and what risks remain during postconflict transition. These findings will provide a better understanding of the types of challenges likely to confront peacekeeping and statebuilding endeavors in other parts of the world.Contributors:Jana Arsovska, Svante Cornell, Johan Engvall, Michael Jonsson, Alexandru Molcean, Niklas Nilsson, Murad Batal al-Shishani, Natalie Verständig.
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample
by
Svensson, Johan
,
Eckerström, Carl
,
Hessen, Erik
in
Alzheimer's disease
,
Classification
,
Clinical progression
2017
Subjective cognitive decline (SCD) and biomarker-based “at-risk” concepts such as “preclinical” Alzheimer's disease (AD) have been developed to predict AD dementia before objective cognitive impairment is detectable. We longitudinally evaluated cognitive outcome when using these classifications.
Memory clinic patients (n = 235) were classified as SCD (n = 122): subtle cognitive decline (n = 36) and mild cognitive impairment (n = 77) and subsequently subclassified into SCDplus and National Institute on Aging–Alzheimer's Association (NIA-AA) stages 0 to 3. Mean (standard deviation) follow-up time was 48 (35) months. Proportion declining cognitively and prognostic accuracy for cognitive decline was calculated for all classifications.
Among SCDplus patients, 43% to 48% declined cognitively. Among NIA-AA stage 1 to 3 patients, 50% to 100% declined cognitively. The highest positive likelihood ratios (+LRs) for subsequent cognitive decline (+LR 6.3), dementia (+LR 3.4), and AD dementia (+LR 6.5) were found for NIA-AA stage 2.
In a memory clinic setting, NIA-AA stage 2 seems to be the most successful classification in predicting objective cognitive decline, dementia, and AD dementia.
Journal Article
Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report
by
Korczyn, A.
,
Traykov, L.
,
Wallin, A.
in
Albumin
,
Alzheimer Disease - diagnosis
,
Alzheimer's disease
2017
Background
Vascular cognitive impairment (VCI) is a heterogeneous entity with multiple aetiologies, all linked to underlying vascular disease. Among these, VCI related to subcortical small vessel disease (SSVD) is emerging as a major homogeneous subtype. Its progressive course raises the need for biomarker identification and/or development for adequate therapeutic interventions to be tested. In order to shed light in the current status on biochemical markers for VCI-SSVD, experts in field reviewed the recent evidence and literature data.
Method
The group conducted a comprehensive search on Medline, PubMed and Embase databases for studies published until 15.01.2017. The proposal on current status of biochemical markers in VCI-SSVD was reviewed by all co-authors and the draft was repeatedly circulated and discussed before it was finalized.
Results
This review identifies a large number of biochemical markers derived from CSF and blood. There is a considerable overlap of VCI-SSVD clinical symptoms with those of Alzheimer’s disease (AD). Although most of the published studies are small and their findings remain to be replicated in larger cohorts, several biomarkers have shown promise in separating VCI-SSVD from AD. These promising biomarkers are closely linked to underlying SSVD pathophysiology, namely disruption of blood-CSF and blood–brain barriers (BCB-BBB) and breakdown of white matter myelinated fibres and extracellular matrix, as well as blood and brain inflammation. The leading biomarker candidates are: elevated CSF/blood albumin ratio, which reflects BCB/BBB disruption; altered CSF matrix metalloproteinases, reflecting extracellular matrix breakdown; CSF neurofilment as a marker of axonal damage, and possibly blood inflammatory cytokines and adhesion molecules. The suggested SSVD biomarker deviations contrasts the characteristic CSF profile in AD, i.e. depletion of amyloid beta peptide and increased phosphorylated and total tau.
Conclusions
Combining SSVD and AD biomarkers may provide a powerful tool to identify with greater precision appropriate patients for clinical trials of more homogeneous dementia populations. Thereby, biomarkers might promote therapeutic progress not only in VCI-SSVD, but also in AD.
Journal Article
Tau-targeting antisense oligonucleotide MAPT Rx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial
by
Mummery, Catherine J
,
Li, Dan
,
Bodenschatz, Ralf
in
Alzheimer Disease - cerebrospinal fluid
,
Alzheimer Disease - drug therapy
,
Alzheimer Disease - genetics
2023
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting antisense oligonucleotide (MAPT
) and reduce tau levels in patients with mild AD. A randomized, double-blind, placebo-controlled, multiple-ascending dose phase 1b trial evaluated the safety, pharmacokinetics and target engagement of MAPT
. Four ascending dose cohorts were enrolled sequentially and randomized 3:1 to intrathecal bolus administrations of MAPT
or placebo every 4 or 12 weeks during the 13-week treatment period, followed by a 23 week post-treatment period. The primary endpoint was safety. The secondary endpoint was MAPT
pharmacokinetics in cerebrospinal fluid (CSF). The prespecified key exploratory outcome was CSF total-tau protein concentration. Forty-six patients enrolled in the trial, of whom 34 were randomized to MAPT
and 12 to placebo. Adverse events were reported in 94% of MAPT
-treated patients and 75% of placebo-treated patients; all were mild or moderate. No serious adverse events were reported in MAPT
-treated patients. Dose-dependent reduction in the CSF total-tau concentration was observed with greater than 50% mean reduction from baseline at 24 weeks post-last dose in the 60 mg (four doses) and 115 mg (two doses) MAPT
groups. Clinicaltrials.gov registration number: NCT03186989 .
Journal Article
Drugs, Guns and Rebellion: A Comparative Analysis of the Arms Procurement of Insurgent Groups in Colombia and Myanmar
2014
Several insurgent groups have financed their arms procurement through drug trafficking, explaining in part the long duration of conflicts in drug producing countries. Incomes generated from this trade do
not
however automatically translate into improved military capabilities, since access to military-grade weapons typically requires tacit or active state support. Hence, two groups with similar types of funding can still have access to very different types of armaments, impacting their operational capability. This paper compares the arms procurement of the Fuerzas Armadas Revolucionarias de Colombia (FARC) and the United Wa State Army (UWSA) in Myanmar. Both insurgent groups have procured arms through networks and with finances from the drug trade. The UWSA's 20,000-strong force and significant armaments, including Man-portable air defense systems (MANPADS) believed to be provided by China, is largely supported by these illicit activities and the networks they provide. FARC has ample access to small arms, the acquisition of which has been financed by taxation of the drug trade. In spite of significant incomes, FARC however until very recently lacked access to MANPADS, a fact which has significantly hampered its ability to withstand the Colombian counterinsurgency campaign, specifically targeted aerial assaults. The exploratory comparisons drawn in this paper offer insights into how insurgent groups can pass a crucial threshold of arms procurement, funded by illicit activities, that renders their dissolution far more difficult, while also highlighting the continued importance of state support in explaining rebel group resilience.
Journal Article
Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders
by
Eckerström, M.
,
Kettunen, P.
,
Eckerström, C.
in
Alzheimer's disease
,
Angina pectoris
,
Biomarkers
2021
Introduction To evaluate the usefulness of the 2018 NIA‐AA (National Institute on Aging and Alzheimer's Association) research framework in a longitudinal memory clinic study with different clinical outcomes and underlying disorders. Methods We included 420 patients with mild cognitive impairment or subjective cognitive impairment. During the follow up, 27% of the patients converted to dementia, with the majority converting to Alzheimer's disease (AD) or mixed dementia. Based on the baseline values of the cerebrospinal fluid biomarkers, the patients were classified into one of the eight possible ATN groups (amyloid beta [Aβ] aggregation [A], tau aggregation reflecting neurofibrillary tangles [T], and neurodegeneration [N]). Results The majority of the patients converting to AD and mixed dementia were in ATN groups positive for A (71%). The A+T+N+ group was highly overrepresented among converters to AD and mixed dementia. Patients converting to dementias other than AD or mixed dementia were evenly distributed across the ATN groups Discussion Our findings provide support for the usefulness of the ATN system to detect incipient AD or mixed dementia.
Journal Article
The impact of blacklists on external deposits: one size does not fit all
2022
Purpose
This study aims to measure the impact of the Non-Cooperative Countries and Territories, Organization for Economic Cooperation and Development and US PATRIOT Act Section 311 blacklists on external deposits from blacklisted jurisdictions into BIS reporting countries in 1996–2008, a period when anti-money laundering-related actions were consistently less stringent than post-2010, to see whether they had an effect even absent the threat of sizable financial fines.
Design/methodology/approach
The study uses descriptive statistics and bivariate and multivariate regressions to analyze the probable impact from blacklists on non-bank external deposits. The country sample is divided into offshore financial centers (OFCs) and non-OFCs and includes 158 non-listed countries. The impact of the blacklists is tested both jointly and individually for the respective blacklists.
Findings
The authors find mixed impact from jurisdictions being blacklisted on the growth rate of stocks of deposits into BIS reporting countries. Effects are often zero, negative in several cases and positive in some cases. This is consistent with the “stigma effect” and the “stigma paradox” in the literature. An overall impact from blacklisting is difficult to discern. Different blacklists had different effects, and the same blacklist impacted countries differently, illustrating the importance of disaggregating the analysis by individual countries.
Research limitations/implications
Interpretation of these data is limited by the absence of comparable data on non-resident deposits in blacklisted jurisdictions.
Practical implications
The impact of a blacklist depends in part on the structure of the listed jurisdictions’ economies, implying that country-specific sanctions may be more effective than blacklists.
Originality/value
This is one of the very few papers to date to rigorously test the impact of blacklists on external deposits.
Journal Article